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BACKGROUND AND AIMS: The serum/plasma proteome was explored for biomarkers to improve the diagnostic ability of CA19-9
in pancreatic adenocarcinoma (PC).
METHODS:A Training Set of serum samples from 20 resectable and 18 stage IV PC patients, 54 disease controls (DCs) and 68 healthy
volunteers (HVs) were analysed by surface-enhanced laser desorption and ionisation time-of-flight mass spectrometry (SELDI-TOF
MS). The resulting protein panel was validated on 40 resectable PC, 21 DC and 19 HV plasma samples (Validation-1 Set) and further
by ELISA on 33 resectable PC, 28 DC and 18 HV serum samples (Validation-2 Set). Diagnostic panels were derived using binary
logistic regression incorporating internal cross-validation followed by receiver operating characteristic (ROC) analysis.
RESULTS: A seven-protein panel from the training set PC vs DC and from PC vs HV samples gave the ROC area under the curve
(AUC) of 0.90 and 0.90 compared with 0.87 and 0.91 for CA19-9. The AUC was greater (0.97 and 0.99, Po0.05) when CA19-9
was added to the panels and confirmed on the validation-1 samples. A simplified panel of apolipoprotein C-I (ApoC-I),
apolipoprotein A-II (ApoA-II) and CA19-9 was tested on the validation-2 set by ELISA, in which the ROC AUC was greater than that
of CA19-9 alone for PC vs DC (0.90 vs 0.84) and for PC vs HV (0.96 vs 0.90).
CONCLUSIONS: A simplified diagnostic panel of CA19-9, ApoC-I and ApoA-II improves the diagnostic ability of CA19-9 alone and
may have clinical utility.
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Diagnostic serum biomarkers for pancreatic cancer are unsatis-
factory (Honda et al, 2005), although many have been investigated
(Grote and Logsdon, 2007). CA19-9, the ‘gold standard’ (Goone-
tilleke and Siriwardena, 2007), has a 79% (range reported in the
literature 70–90%) sensitivity and 82% (68–91%) specificity.
Although grossly elevated CA19-9 predicts unresectable disease
(Maithel et al, 2008) and prognosis for chemoradiotherapy (Berger
et al, 2008), 10–15% of patients cannot produce CA19-9 because of
Lewis-negative genotype (Kawai et al, 2008). In addition, serum
CA19-9 is elevated in other malignancies and benign disorders
(Kim et al, 2004). Recently, the necessity for a multivariate serum
marker has been proposed (Grote and Logsdon, 2007).
The low-molecular-weight proteome (o10kDa) is a rich source
of new potential biomarkers, but these do not resolve easily
with 2D gel electrophoresis (Issaq et al, 2002; Wang et al, 2003).
Mass spectrometric technologies perform optimally in the low-
molecular-weight range and early reports using surface-enhanced
laser desorption and ionisation time-of-flight mass spectrometry
(SELDI-TOF MS) have been promising (Bhattacharyya et al, 2004;
Koopmann et al, 2004; Honda et al, 2005). Five groups have
studied a serum protein panel using SELDI in combination with
CA19-9 and have shown that such a combination of proteins is
superior to CA19-9 alone (Koopmann et al, 2004; Honda et al,
2005; Ehmann et al, 2007; Guo et al, 2009; Navaglia et al, 2009).
Despite the similar findings of the above SELDI-based papers,
there is no validated biomarker or biomarker panel for pancreatic
adenocarcinoma (PC). Consequently, this paper describes an
international study using SELDI-TOF MS to identify biomarkers
that are followed by the use of ELISA to validate these on a further
set of samples in which the disease controls (DCs) had severe
pancreatic pathology. This work therefore aims to develop
improved biomarkers that would be useful in the diagnosis of
patients at an increased risk of pancreatic cancer.
MATERIALS AND METHODS
Clinicopathological details and sample collection
A total of 319 samples were obtained with patient consent.
Training serum samples were obtained from 160 patients (the
Training Set) managed at Centre-1 (Sydney, Australia) and their
protein panels were validated against 80 plasma samples collected
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sfrom subjects treated at Centre-2 (Verona, Italy; Validation-1
Set; Table 1). The samples were treated similarly with aliquots
stored at  801C until analysis. Further confirmation of the
findings was undertaken using ELISA methodology on a second
set of 79 samples (Validation-2 Set), obtained from centre-1 from
33 PC patients, 28 DCs and 18 healthy volunteers (HVs). These
controls were matched for age and sex. All DCs had pancreatico-
biliary pathology requiring surgical or endoscopic intervention
(Table 1).
Union Internationale Contre le Cancer (UICC) (Sobin, 2009)
classification was used to stage the PC patients.
The study was approved by the ethics committees of the
Northern Sydney Health Human Research, Sydney, Australia and
the University of Verona, Verona, Italy.
Preparation of serum or plasma for SELDI analysis
Serum or plasma was diluted 1:1 with denaturing buffer (8 M urea/
1% CHAPS), and then centrifuged at 12000r.p.m. for 5min). The
supernatant was diluted 1:25 with trifluoroacetic acid (TFA),
added to 50% acetonitrile/0.5% TFA, spotted on a hydrophobic
(H50) protein chip array and processed as previously described
(Scarlett et al, 2006). The protein chip arrays were analysed using
the Bio-Rad Protein Biological System IIc ProteinChip Reader
(Bio-Rad Hercules, CA, USA).
SELDI-TOF MS analysis
Mass spectra were generated in the m/z range 2500–75000 with a
laser intensity setting of 220 (arbitrary units) and detector
sensitivity set at 8. The laser was optimised for 4000–20000 m/z
peaks, whereas peaks o1000 m/z were deflected from the detector.
Mean values from duplicate samples were used in subsequent
analyses. The m/z value for each of the peaks was determined using
external calibration with known standards (Sigma-Aldrich, St Louis,
MO, USA): bovine insulin (5734.51 þ1H), equine cytochrome
c (12361.96 þ1H), equine apomyoglobin (16952.27 þ1H) and
rabbit muscle aldolase (39212.28 þ1H). Spectra were analysed using
the Ciphergen Protein Chip Software Version 3.1 (Bio-Rad).
Protein purification and identification
The proteins of interest were size fractionated on a Superose 12 HR
10/300 GL column (Amersham Pharmacia Biotech, Uppsala,
Sweden), equilibrated and eluted with 0.1 M acetic acid/0.1 M NaCl
(pH 3.0) and fractions were monitored on SELDI using normal
phase NP20 chips. Pooled fractions containing maximum activity
were subjected to reverse-phase high-performance liquid chroma-
tography (HPLC) on a 4.6 250mm Jupiter 5mm, 300A ˚ C18 column
(Phenomenex, Torrance, CA, USA) after 30min of gradient elution
(15–60% acetonitrile in 0.1% TFA), and fractions were again
monitored by SELDI-TOF MS on NP20 chips. The fraction
containing the peaks of interest was lyophilised and then sent to
the Bioanalytical Mass Spectrometry Facility (University of New
South Wales, Sydney, Australia) for identification by tryptic
peptide mass fingerprinting and MS sequencing. To confirm
the protein identities, a SELDI immunoadsorption approach was
performed. In this instance, a rabbit polyclonal Apolipoprotein C-I
(ApoC-I) antibody (AbCam, Cambridge, UK) was bound to an
RS100 protein chip array and analysed on the SELDI-TOF MS.
The three protein peaks at m/z 16989, 17132 and 17247 were
identified by a different strategy from above, following the report
of Ehmann et al (2007), which described protein peaks at m/z
17270 and 17390 in human serum SELDI profiles as apolipopro-
tein A-II (ApoA-II) homodimers. The serum of patients suffering
from PC and the purified human plasma ApoA-II (Sigma-Aldrich,
Paris, France) were directly submitted to an RS100 preactivated
chip coupled with ApoA-II antibody (AbCam, Paris, France).
Western blotting validation
PC serum samples and purified human plasma ApoA-II were treated
with 20mM dithiothreitol (DTT) from 0 to 4h, respectively, and
subjected to western blotting analysis with anti-ApoA-II antibody
(AbCam) as described in a previous study (Xue et al,2 0 0 9 ) .
Statistical analysis
The raw peak intensity data were normalised using the total ion
current between 2500 and 75000 m/z and peak detection was
performed using the Biomarker Wizard utility (Version 3.1,
Bio-Rad). Sample group statistics were performed on peak
intensity values for profiles of PCs vs DCs and HVs. Univariate
analysis of individual peaks was performed using the non-
parametric Mann–Whitney U-test with significance considered
at Po0.05. The discriminatory power for each marker was
characterised by receiver operating characteristic (ROC) area
under the curve (AUC) analysis and the AUCs were compared
using the Hanley and McNeil method (Hanley and McNeil, 1983;
SPSS software Version 12.0, Chigaco, IL, USA). Values of ROC
AUC are presented (Scarlett et al, 2006) with their 95% confidence
intervals.
Co-correlation of protein peaks was examined by Spearman’s
non-parametric correlation coefficients because of the wide
Table 1 Detail of patient groups
Training
SELDI
Validation-1
SELDI
Validation-2
ELISA
nn n
Pancreatic ductal adenocarcinoma 38 40 33
Male 20 23 15
Female 18 17 18
Stage I 7 — 1
Stage IIa 5 4 7
Stage IIb 8 36 14
Stage IV 18 — 11
Disease control 54 21 28
Male 28 18 16
Female 26 3 12
Cholelithiasis 17 2
Choledocholithiasis 6
Intraductal papillary mucinous
neoplasm
6— 1
Carotid artery stenosis — 6
Mucinous cystadenoma 5 — 2
Neuroendocrine (islet cell)
tumour
5 — 7 (4)
Gallstone pancreatitis 4 — 2
Chronic pancreatitis 4 1 2
Benign stricture 2
Hernia 3 2
Acute cholecystitis — 3
Other
a 10 7 3
Healthy volunteer 68 19 18
Male 28 12 9
Female 40 7 9
Abbreviation: SELDI¼surface-enhanced laser desorption and ionisation. The number
in brackets indicates malignant islet cell tumours.
aOther includes: Training
Set – villous adenoma (n¼2), serous cystadenoma (n¼2), pancreatic pseudocyst
(n¼2), solid pseudopapillary tumour (n¼1), Caroli’s disease (n¼1), gastro-
oesophageal reflux (n¼1) and ruptured appendix (n¼1); Validation-1 Set – leg
ischaemia (n¼2), rectal bleeding (n¼2), diaphragmatic hernia (n¼1), phlebitis
(n¼1) and haematological disorder (n¼1); and Validation-2 Set – solitary fibrous
tumour, granulomata, intrapancreatic pseudocyst.
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svariance of the data for protein values, CA19-9 and bilirubin
values.
Development and validation of candidate biomarker
models
Development Biomarker panels were developed on the centre-1
serum cohort (n¼160) using the multivariate binary logistic
regression with ten-fold cross-validation technique previously
described (Scarlett et al, 2006), which had been developed by
Ambroise and McLachlan (Ambroise and McLachlan, 2002). Only
serum peaks that significantly discriminated PCs from DCs or
from HVs at Po0.01 were considered for multivariate analysis.
This repeated random sampling procedure allowed for the
correction of selection bias and enabled the calculation of unbiased
estimates of sensitivity and specificity, overall accuracy and ROC
AUC values with their 95% confidence intervals of the candidate
biomarker panels.
Validation The models developed in the training phase were then
tested on the independent centre-2 plasma samples (n¼80).
Likelihood ratios (LRs) were calculated for each model to estimate
the ratio of the likelihood of the test result in patients with disease
to the likelihood of the same test result in patients without disease.
Results with an LR of 410 or o0.1 effect a substantial change on
disease likelihood over a broad range of pre-test estimates,
whereas an LR of 1.0 leaves the likelihood of disease unchanged
(Brown and Reeves, 2003).
ELISA measurement of serum levels of CA19-9, ApoA-II
and ApoC-I
Having developed the protein biomarker panel with SELDI, further
confirmation was sought using ELISA as follows. Duplicate serum
or plasma levels of CA19-9 were measured by ELISA kit (Alpha
Diagnostic International, San Antonio, TX, USA) for which normal
values were set at o37Uml
–1. Similarly, levels of ApoA-II and
ApoC-I were measured by AssayMax ApoA-II ELISA kit and
AssayMax ApoC-I ELISA kit (AssayPro, St Charles, MO, USA),
respectively. Absorbance was measured at 450nm on a microplate
reader (Tecan, Salzburg, Austria) within 10min.
RESULTS
Patient characteristics
Three separate groups of subjects were studied. The initial training
set from centre-1 consisted of 160 samples: 38 from PC patients (21
studied before surgery and 17 before palliative treatments), 54 DC
samples from patients with other pancreatico-biliary disorders and
68 samples from HVs (Table 1). Although 18 of 39 PC and 10 of 54
DC patients had elevated serum bilirubin values, there was a
significant difference between the PC and DC groups for mean
bilirubin and other liver function test values (Table 2). The
validation-1 samples from centre-2 were obtained from 40 PC
subjects taken before resection, 21 DCs from patients requiring an
acute admission and 21 HV subjects (Table 1). Of the PC patients
from centre-2, 20 had elevated serum bilirubin values.
Validation-2 samples were from a further 79 patients from
centre-1: 33 PC samples (21 from patients who underwent
resection), 28 DC subjects (18 underwent pancreatic resection
whereas 10 had therapeutic endoscopic retrograde cholangiopan-
creatography (ERCP)) and 18 HV subjects. The DCs and HVs had
similar age and sex distribution (Table 1). In the validation-2
groups, bilirubin was elevated in 21 of 33 with PCs and 10 of 28
DCs (w
2¼2.1, NS), but the median values were marginally different
(P¼0.047). The HVs had normal liver function values.
Serum CA19-9 values of training and validation-1 samples
Blood CA19-9 levels were elevated in 63 of 78 PCs, 20 of 75 DCs
and 15 of 85 HVs with greater mean (± s.e.m.) values in PC
compared with DC and HV patients (CA19-9¼1192.2 (±477.0),
34.3 (±5.0) and 19.7Uml
–1(±2.1), respectively; Po0.001). Mean
CA19-9 values were also higher in the stage IIb and IV patients
(2212±1354Uml
–1) compared with the early stage I and IIa
patients (163±19Uml
–1), but this was not statistically significant
using the Mann–Whitney test.
Development of diagnostic models from SELDI analysis
Differences in SELDI profiles were observed between PC, DC and
HV subjects using the H50 protein chip array (Supplementary
Figure S1). In all, 62 individual protein peaks observed in the m/z
range 3000–20000 were analysed. In the training set samples, 21
Table 2 Mean and s.e.m. of age and biochemical indices for patient groups
Pancreatic cancer Disease controls
P-value
Values Set Mean s.e.m. or range Mean s.e.m. or range PC vs DC
Age (years) Training 70.9 (28–80) 62.7 (32–81) NS
Validation-2 69.7 (32–81) 57.1 (18–89) NS
Urea (mmoll
–1) Training 5.9 0.5 5.1 0.4 NS
Validation-2 5.8 0.4 5.6 0.6 NS
Bilirubin (mmoll
–1) Training 144 33 18 3 0.001
Validation-2 88 20 49 21 0.01
Albumin (gl
–1) Training 35.1 1.2 41.1 0.8 0.001
Validation-2 35.5 1.1 39.4 1.1 0.017
AST (IUl
–1)
a Training 111 19 50 10 0.001
Validation-2 98 19 53 9 0.049
ALT (IUl
–1)
a Training 154 28 76 21 0.005
Validation-2 143 32 94 26 NS
ALP (IUl
–1)
a Training 362 60 101 14 0.001
Validation-2 316 45 172 23 0.007
GGT (IUl
–1)
a Training 489 102 130 43 0.001
Validation-2 561 111 208 49 0.006
CA19-9 (Ul
–1)
a Training 1594 960 32 7 0.001
Validation-2 1466 922 31 9 0.001
Abbreviations: ALP¼ alkaline phosphatase; AST¼ glutamic-oxaloacetic transaminase; ALT¼ glutamic-pyruvic transaminase; CA19-9¼ carbohydrate antibody 19-9;
DC¼ disease control; GGT¼ g-glutamyltransferase; NS¼ not significant; PC¼ pancreatic cancer.
aResults are for serum values. P-value indicates Mann–Whitney U-test result.
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speaks were found to be differentially expressed between PCs and
DCs. These individual putative tumour markers had ROC AUC
values ranging from 0.62 to 0.81, with 14 upregulated in PC
patients (Supplementary Table S1). Logistic regression with ten-
fold cross-validation was applied to the subset of protein peaks
that were differentially expressed between PCs and DCs to a
significance of Po0.01 as determined by univariate analysis
(Supplementary Table S1). This selected a panel of seven protein
peaks (m/z 6420, 8451, 8614, 9137, 9626, 9694 and 12862) that
correctly classified 74% of PC and 87% of DC serum samples (ROC
AUC: 0.90 (0.85–0.96), Supplementary Table S1 and Figure 1A).
Discriminatory power was further improved by including the
values of the tumour marker CA19-9 into the model. This model
correctly classified 89% of PC and 96% of DC serum samples (ROC
AUC: 0.97 (0.93–0.99), Supplementary Table S1 and Figure 1A).
When the protein peak model was applied to the validation-1
samples, 90% of PC and 67% of DC samples were correctly
classified (ROC AUC: 0.88 (0.79–0.96), Supplementary Table S1
and Figure 1B). When CA19-9 was included in the model, 93% of
PC and 71% of DC samples were correctly classified (ROC AUC:
0.93 (0.86–0.99)). For both the training and validation-1 cohorts,
the ROC AUC values were significantly increased by the addition
of CA19-9 (Po0.05) and were significantly greater than that for
CA19-9 alone (Figures 2C and D).
PC vs HV serum
In all, 18 peaks were found to be differentially expressed between
PCs and HVs, 13 with a P-value p0.01, using logistic regression
analysis (Supplementary Table S1). The ten-fold cross-validation
approach selected a final panel of four peaks (m/z 6618, 16989,
17132 and 17247) that correctly classified 71% of PC and 96%
of HV serum samples (ROC AUC: 0.90 (0.84–0.96), Supplementary
Table S1 and Figure 1C), which was similar to the AUC of
CA19-9 (ROC AUC: 0.914 (0.839–0.989)). When CA19-9 was added
to the protein panel, the discriminatory power was better (Po0.05)
than for the protein panel or CA-19-9 alone – 92% of PC and
97% of HV samples were correctly classified (ROC AUC: 0.99
(0.98–1.00)).
When the logistic regression equation from the training set
was applied to the validation-1 sample set, 90% of PC and 74% of
HV serum samples were correctly classified (ROC AUC: 0.90
(0.81–0.98), Supplementary Table S1 and Figure 1D). Again,
the addition of CA19-9 significantly improved (Po0.05) the
classification, identifying 93% of PC and 84% of HV samples
(ROC AUC: 0.96 (0.91–1.00)), which was greater than that for
CA19-9 alone (ROC AUC: 0.81 (0.61–0.92), but this did not reach
significance.
Testing for co-correlation of the protein values
Spearman’s correlation coefficients for the variables selected in the
above protein panels (Supplementary Table S2) indicate that these
proteins were associated with one of two groups by close
correlation. One group was closely correlated with the m/z 6420
peak and the others were closely correlated with the m/z 17247
peak. Subsequent analysis of the identities of these peaks clarified
this correlation.
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Figure 1 Receiver operator characteristic (ROC) curves for discrimination of pancreatic adenocarcinoma (PC) from disease controls (DCs) and healthy
volunteers (HVs) in both the centre-1 and centre-2 cohorts. The protein panel derived from ten-fold cross-validation (solid line), CA19-9 (dashed line)
and biomarker panel þ CA19-9 (dotted line). (A)P Cvs DC (centre-1): ROC AUC¼0.90 for the biomarker panel, 0.87 for CA19-9 and 0.97 for
the biomarker panel þ CA19-9. (B)P Cvs DC (centre-2): ROC AUC¼0.88 for the biomarker panel, 0.75 for CA19-9 and 0.93 for the biomarker panel
þ CA19-9. (C)P Cvs HV (centre-1): ROC AUC¼0.90 for the biomarker panel, 0.91 for CA19-9 and 0.99 for the biomarker panel þ CA19-9. (D)P Cvs
HV (centre-2): ROC AUC¼0.90 for the biomarker panel, 0.81 for CA19-9 and 0.96 for the biomarker panel þ CA19-9.
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Figure 2 Purification, identification and validation of the apparent 6.6kDa proteins from the serum of a patient with pancreatic adenocarcinoma.
(A) Proteins from serum were run through a Superose 12 HR 10/300 GL column, eluted with 0.1 M acetic acid/0.1 M NaCl (pH 3.0) and fractions were
monitored by SELDI-TOF MS using NP20 chips. (B) Pooled fractions were further purified by reverse-phase HPLC with a 40min 15–60% acetonitrile
gradient in 0.1% trifluoroacetic acid and fractions were monitored by SELDI-TOF MS using NP20 chips. The fraction containing the 6.6kDa proteins (circled)
was then lyophilised and sent to BMSF for identification. (C) Identification of the 6.6kDa proteins was validated using a SELDI immunoassay approach
(RS100 antibody array).
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sProtein purification and identification
Serum samples that showed high m/z 6420 and 6618 peak
intensities were purified for identification of the apparent
6.6kDa proteins. The protein fractions were monitored on SELDI
using NP20 chips (Figure 2A). Pooled fractions containing
maximum activity were further purified using HPLC and again
monitored on NP20 chips (Figure 2B). The fractions containing the
peaks of interest were lyophilised for identification by tryptic
peptide mass fingerprinting and MS sequencing. The m/z 6618
peak was identified as ApoC-I from three peptides that covered
38.5% of the amino acid sequence. To confirm the protein
identities obtained from sequencing, a SELDI immunoadsorption
approach was performed using an ApoC-I antibody bound to an
RS100 protein chip array. The m/z 6420 and 6618 peaks were
captured with high intensity with minimal nonspecific binding
observed for the affinity-purified IgG control (Figure 2C).
The m/z 8614, 16989, 17185 and 17247 proteins were confirmed
as ApoA-II isoforms by examining samples of serum and purified
human ApoA-II. Human ApoA-II not only showed the appearance
of three major isoforms, m/z 16989, 17185 and 17247, but also of a
peak at 8614. A similar pattern was observed in the plasma
specimens (Figure 3 Ae) in SELDI MS profile. Using SDS–PAGE
according to Gillard et al (2005), specimens of purified ApoA-II
and serum samples from PC patients were reduced for 3h using
20mM DTT. This resulted in a loss of the 17-kDa band and an
increase in the 8.6-kDa band, which is consistent with reduction of
disulfide-linked homodimers.
The PC serum samples and purified human plasma ApoA-II
were treated with 20mM DTT from 0 to 4h. The reduced samples
were then submitted to western blotting analysis with anti-ApoA-II
antibody. Figure 3B shows that both crude serum and purified
ApoA-II contained the ApoA-II dimer (B17.2kDa) and the bands
disappeared after reduction by DTT. Furthermore, the band at
8.6kDa was concomitantly increased in intensity upon DTT
treatment. Figures 3C and D show the differences in concentration
of ApoC-I and ApoA-II in non-reducing conditions according to
Gillard et al (2005) on western blot and the semiquantitative
expression undertaken in 15 serum samples from each of the PC,
DC and HV subjects.
Simplified diagnostic panel
Because of the high correlation coefficients between all of the
proteins in the diagnostic panels to either ApoC-I or ApoA-II, a
simplified diagnostic panel was proposed combining the ApoC-I
m/z 6420 peak and the ApoA-II m/z 8614 with CA19-9. This
combination was used to examine the diagnostic effectiveness in
the four different patient groups and showed strong ROC AUC
values of 0.99 for PC vs HV in the training set, 0.95 for PC vs HV in
the validation-1 set, 0.94 for PC vs DC in the training set and 0.92
for PC vs DC subjects in the validation-1 set (Figures 4A–D). The
positive and negative LRs for the above comparisons were 16.5,
5.4, 6.7 and 4.7 and 0.06, 0.11, 0.07 and 0.19, respectively,
indicating that this test would make a useful contribution to
clinical decision making but would not be useful for screening
purposes.
ELISA validation
ELISA mean (s.e.m.) measurements on the HV, DC and PC
validation-2 set for ApoA-II were 55 (2), 47 (1) and 44gl
–1(1) and
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Figure 3 (A) Plots of peak height against m/z for the identification of ApoA-II isoforms using SELDI RS100 profiles. (a) ApoA-II purified human plasma
ApoA-II (Sigma-Aldrich) IgG, (b) serum without IgG, (c) purified human ApoA-II on ApoA-II antibody-enriched chip indicating a number if peaks B8603
indicating monomer and 17132 indicating dimer, (d) purified ApoA-II treated with 20mM DTT for 3h on antibody-enriched chip, (e) serum on ApoA-II
antibody-enriched chip and (f) purified ApoA-II treated with 20mM DTT for 3h on antibody-enriched chip. (B) Western blotting analysis of the effect of 0 to
4h of 20mM DTT reduction on a serum sample and on purified human plasma ApoA-II. (C) Western blot of the expression of ApoC-I and B17kDa ApoA-II
in five pancreatic cancer samples (PC), five disease control samples (DC) and five human volunteer samples (HV). (D) Plot of mean and s.d. band intensity
(% of HV) as semiquantified by Pro-Gel scanning (Gel-Pro Analyzer Properties) for PC samples (n¼15), DC samples (n¼15) and HV samples (n¼15).
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sfor ApoC-I were 107 (4), 101 (6) and 124gl
–1(12). For ApoC-1 the
difference between DCs and PCs indicated a trend to significance
at P¼0.07 and the mean ApoA-II values were different between
HVs and PCs (P¼0.001), whereas the mean differences between
DCs and PCs were not significant. Although there were significant
differences between the PC and DC patients in the values of
bilirubin and other liver function tests, these were less significant
than those from the training sets (Table 2). ROC analysis
confirmed a significant diagnostic influence of the combination
of two proteins, ApoA-II and ApoC-I, with AUC of 0.86
(0.76–0.96) for PC vs HV and 0.68 (0.55–0.81) for PC vs DC
patients. The addition of these proteins to CA19-9 improved the
ROC AUC compared with CA19-9 alone to 0.96 (0.90–1.0) vs 0.90
(0.80–0.99) for HV samples and 0.90 (0.82–0.98) vs 0.84
(0.74–0.95) for DC samples (Figure 5). Multivariate stepwise
backward analysis showed significance for the combined panel but
no influence from the addition of bilirubin, albumin or serum
alkaline phosphatase was observed. Figure 5C shows the prob-
ability of diagnosing pancreatic cancer compared with benign
disease (HV and DC cases combined), derived from binary
logistic regression using the ELISA values for ApoA-II, ApoC-I
and CA19-9.
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Figure 4 ROC curves for the performance of the simplified biomarker panel (CA19-9 and the protein peak heights for m/z 6420 (ApoC-I) and 17247
proteins (ApoA-II)). (A–D)P Cvs DC for centre-1 samples, PC vs DC for centre-2 samples, PC vs HV for centre-1 samples and PC vs HV for centre-2
samples are shown (see text for AUC values).
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ApoA-II, ApoC-I and CA19-9, dashed lines indicate CA19-9 whereas solid lines indicate the combined protein panel of ApoA-II and ApoC-I (see text for
AUC values). (C) The probability of diagnosing PC as separate from benign cases (combined HV and DC) using binary logistic regression on the ELISA
values of ApoA-II, ApoC-I and CA19-9.
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sDISCUSSION
This international collaborative study shows the utility of SELDI-
TOF MS for identification of potential diagnostic biomarker panels
that have been confirmed on two independent sample sets. The
significant proteins in the diagnostic panel were identified as
ApoA-II and ApoC-I. This allowed for a simplified panel, the
efficacy of which was confirmed on validation-2 samples by ELISA.
Although this study has similar motives to previous studies using
SELDI-TOF MS (Koopmann et al, 2004; Honda et al, 2005; Ehmann
et al, 2007; Guo et al, 2009; Navaglia et al, 2009), important new
findings are described. Both ApoC-I (Takano et al, 2008) and
ApoA-II (Ehmann et al, 2007) have been identified in previous
studies, but they have not been used in combination, in which they
seem to provide independent contributions to the diagnostic panel.
The sensitivities and specificities of new individual peaks were
similar to that of CA19-9 in discriminating PCs from both DCs and
HVs, but importantly discriminatory power was significantly
improved by multi-protein marker models that included CA-19-9.
The robustness of the model was shown by the fact that although
developed on a training set of serum samples, it was able to be
validated on plasma samples (Banks et al, 2005). Further support
for the diagnostic capacity of this protein panel was confirmed by
ELISA on a separate sample set.
Both the PC vs DC and PC vs HV classification models improved
the discriminatory power when compared with CA19-9 alone. The
importance of CA19-9 as a diagnostic marker of pancreatic cancer
(Goonetilleke and Siriwardena, 2007) is confirmed by this study,
but its discriminating ability is significantly improved by the
SELDI-derived diagnostic panels. Furthermore, the overall accu-
racy of the combined results indicates that these diagnostic models
may become clinically useful in high-risk patient groups. However,
because of the low prevalence of pancreatic cancer, a much greater
accuracy would be required before these diagnostic panels could
be clinically useful in an asymptomatic population (Bhattacharyya
et al, 2004).
ApoA-II was observed in both the monomeric form of m/z 8614
and in the dimers of m/z 16989, 17185 and 17247 in the SELDI MS
profiles. In human plasma or serum, ApoA-II mainly exists as a
disulfide-linked homodimer at approximately 17.3kDa (Gillard
et al, 2005). There seems to be a number of isoforms that may
account for the smaller adjacent peaks of m/z 16989 and 17132.
The apolipoproteins lie on the surface of lipid particles and have
an important role in directing the fate of these particles to different
organs for metabolism. The precise function of ApoA-II is not
entirely clear but it is suggested that ApoA-II is rich in HDL
particles that promote the formation of atheroma (Stein et al,
1995). The exact metabolism of ApoA-II is not completely known.
It has a diagnostic role in prostate carcinoma that has been shown
to release ApoA-II (Malik et al, 2005). In comparison with
pancreatic cancer, in which low levels are diagnostic, in prostate
cancer high levels are diagnostic.
Five research groups using SELDI-TOF for the identification of
serum markers of pancreatic cancer have also developed multiple
marker panels that include CA19-9 (Koopmann et al, 2004; Honda
et al, 2005; Ehmann et al, 2007; Guo et al, 2009; Navaglia et al,
2009). Koopmann et al (2004) used IMAC-Cu
2þ and weak cationic
exchange protein chips and found a two-peak panel that
differentiated PC samples from HVs, whereas a three-peak panel
distinguished PCs from DCs. These panels performed better than
CA19-9 alone, but when used in combination, the diagnostic
accuracy was further improved. Guo et al, (2009) used strong
anion-exchange protein chips to show that the three protein
biomarkers, m/z 4155, 4791 and 28068, are more accurate than
CA19-9 in differentially diagnosing pancreatic cancer. The larger
peak was identified as the protein C14orf16 that is highly expressed
in cancer tissue, although the function of this protein is not fully
elucidated. Yu et al (2005) used the Biomarker Patterns software
(Bio-Rad) to develop a classification tree that includes six peaks
that differentiate cancer from non-cancer with high sensitivity and
specificity without CA19-9 in 100 subjects, using IMAC-Cu
2þ
protein chips, and recently this group has shown high sensitivity
and specificity of the protein panel. Honda et al (2005) used three
protein chip types (IMAC-Cu
2þ, H50 and CM10) on 24 subjects,
and developed training models using a support vector machine
algorithm that selected four peaks, three from the CM10 protein
chip and one from the H50, which when combined could
distinguish pancreatic cancer from healthy controls with high
sensitivity and specificity. The SELDI-derived panel was superior
to that of CA19-9 alone, but was further improved in combination
with CA19-9. A fifth recent study compared serum from cancer
patients and healthy volunteers and showed that a panel of three
proteins had a sensitivity of 83% and a specificity of 96% when
tested in an independent validation set of samples. Interestingly,
ApoA-II was identified, along with ApoA-I and transthyretin
(Ehmann et al, 2007). These proteins are produced by the liver and
have important roles in lipid transport, and although their full
function is not understood, they are components of HDL.
Although these studies report differing numbers and peaks that
constitute the diagnostic panels that show promise, each lacks the
identification of many of the proteins of interest.
Our findings that lipoproteins are perturbed in pancreatic caner
suggest that lipid metabolism is important for such tumours. This
is supported by cell culture studies that show greater cell growth in
the presence of lipid (Wang et al, 2009). Therefore, it is interesting
that the apolipoproteins seen to be markers of pancreatic cancer
are both involved with lipid transport. ApoA-II is a component of
HDL subclass 3 in which it combines with ApoA-I and results in a
smaller particle size by increasing its hydrophobic properties
(Gao et al, 2009). This acts as a counter to the cardio-protective
effects of ApoA-I. However, the exact function of ApoA-II is
unclear (Blanco-Vaca et al, 2001; Gao et al, 2009). It is possible that
ApoA-II helps direct lipid to the cancer. However, there are a
number of alternative reasons that the concentration of apolipo-
proteins may be depressed in patients with pancreatic cancer:
weight loss (Ng et al, 2010), liver dysfunction (Tacikowski et al,
2000) and diabetes (Onat et al, 2009). It will be important to study
this further to determine whether this effect is directly related to
PC demand for nutrition or whether they are an epiphenomenon
of the weight loss associated with the cancer.
This study found that the m/z 6618 peak, identified as ApoC-I,
was most frequently selected for the PC vs HV model by ten-fold
cross-validation. Investigation of the serum/plasma MS literature
revealed that ApoC-I exists in human serum as ApoC-I
(B6630Da) and a truncated isoform that lacks N-terminal
Thr-Pro- (6432Da) (Jin and Manabe, 2005). ApoC-I has an
important role in controlling plasma lipid metabolism, but little
is known about its role in the cancer process (Bondarenko et al,
1999). Genetic upregulation of ApoC-I has been shown in gastric
cancer (Oue et al, 2004), whereas in a recent breast cancer study
ApoC-I formed part of a multi-protein index (developed from
SELDI analysis) that could predict metastatic relapse in high-risk
primary breast cancer patients receiving adjuvant chemotherapy
(Goncalves et al, 2006). ApoC-I has also been shown in pancreatic
cancer and is suggested to be associated with infiltrating
macrophages within the juxtatumoural stroma (Ricci et al, 2005).
Ricci et al (2005) suggested that this may be an indication of
direct communication between stroma and cancer cells and
provides evidence of a response to infiltrative growth that may
predominate in tumour–stromal interactions independent of
cancer type.
The inflammatory process associated with cancer may have
important prognostic implications (Pine et al, 2009) and the
specificity of this may provide opportunities for biomarker
discovery. Using electrospray ionisation (ESI) ion-trap tandem
MS (ESI-MS) to explore the differences between human pancreatic
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scancer sera and normal sera, Hanas et al (2008) revealed greater
heterogeneity in cancer sera, especially in the low-mass region.
Using a statistical bootstrap approach, they showed that three
large-mass proteins involved in inflammatory responses were
elevated in pancreatic cancer sera: a-2 macroglobulin, cerulo-
plasmin and complement 3C. Firpo et al (2009) also improved the
discriminatory power of CA19-9 when used with two acute-phase
proteins: haptoglobin and serum amyloid A. In our validation-2
data, ApoC-I levels correlated with white cell count; although
ApoC-I is an inflammatory marker, the results confirm those of
Takano et al (2008) that ApoC-I is also a potentially useful marker
for pancreatic cancer.
This international collaborative study confirms the usefulness
of SELDI-TOF MS for exploration of low-mass proteome (Guo
et al, 2009) in which there are important signatures of the cancer
process (Navaglia et al, 2009) when PC is resectable. Because of the
complex cancer process, a panel of biomarkers is likely to be useful
in high-risk groups of patients. Further exploration of the exact
function of these proteins may provide insights into PC. It will be
important to discover how early in the tumourigenic process these
proteins become altered, and whether these panels of proteins
are capable of diagnosing curable PC.
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